Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690444 | 1.00 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL686694 | 1.00 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31571912 | 0.95 | TGFBR1 (0.61) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31571914 | 0.93 | TGFBR1 (0.59) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL5013249 | 0.90 | FOLH1 (0.50) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL5013251 | 0.90 | FOLH1 (0.50) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL8376832 | 0.87 | TGFBR1 (0.46) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL1455722 | 0.86 | FOLH1 (0.58) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL1455716 | 0.86 | FOLH1 (0.58) | TGFBR1FOLH1SLC6A5GSRCPB2 | |
| SCHEMBL31243301 | 0.84 | TGFBR1 (0.44) | TGFBR1FOLH1SLC6A5GSRCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211150-A1 | PEGYLATED RESOLVING AGENTS FOR IMPROVED RESOLUTION OF RACEMIC MIXTURE | KARIMIAN, KHASHAYAR (IR) | 2019-07-11 | — | — | US | disclosed |
| EP-1254092-B1 | RESOLUTION OF DL-RACEMIC MIXTURES | DEGUSSA (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-6673942-B1 | PREFERENTIAL CRYSTALLIZATION, PHYSICAL SEPARATION | DEGUSSA AG (DE) | 2004-01-06 | — | — | US | disclosed |
| EP-1254092-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | Degussa AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058835-A1 | RESOLUTION OF DL-RACEMIC MIXTURES | DEGUSSA AG (DE) | 2001-08-16 | — | — | WO | disclosed |
| EP-0225503-B1 | RESOLUTION SYSTEM | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1989-08-02 | — | — | EP | disclosed |
| EP-0225503-A1 | Resolution system | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211150-A1 | PEGYLATED RESOLVING AGENTS FOR IMPROVED RESOLUTION OF RACEMIC MIXTURE | SRR, DEGS1, PHOSPHO1 | TGFBR1 3970/4885FOLH1 3447/4885SLC6A5 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.